Clinical Cancer Research

Clinical Cancer Research
Title	Clinical Cancer Research
Discipline	Oncology
Publisher	American Association for Cancer Research
Country	United States
Frequency	Monthly
Established	1995
Impact factor	10.107

Contents

Clinical Cancer Research

Clinical Cancer Research is a peer-reviewed medical journal focusing on oncology clinical trials, translational research, and biomarkers that bridge laboratory discoveries with patient care. It publishes original articles, reviews, and commentaries that influence practice in settings such as National Cancer Institute, Mayo Clinic, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute. The journal serves investigators affiliated with institutions like Harvard Medical School, Johns Hopkins University, Stanford University School of Medicine, and multinational consortia including European Organisation for Research and Treatment of Cancer.

Introduction

Clinical Cancer Research covers studies conducted across major centers such as MD Anderson Cancer Center, UCSF Medical Center, Karolinska Institutet, and Princess Margaret Cancer Centre, and often features collaborations with pharmaceutical companies including Pfizer, Roche, Novartis, Merck & Co., and AstraZeneca. Topics frequently relate to landmark trials associated with investigators at National Institutes of Health, cooperative groups like Children's Oncology Group, regulatory interactions with Food and Drug Administration, and guideline influences from organizations such as American Society of Clinical Oncology. Articles often cite pivotal work connected to figures like James Allison, Tasuku Honjo, Tony Ho, and institutions involved in immunotherapy, targeted therapy, and radiotherapy research.

The journal emphasizes trial methodologies used in phase I trials at centers like Royal Marsden Hospital and phase III trials coordinated by groups such as European Society for Medical Oncology and Alliance for Clinical Trials in Oncology. It reports adaptive designs influenced by statistical developments from teams at University of Pennsylvania, Johns Hopkins Bloomberg School of Public Health, and Columbia University Irving Medical Center, and regulatory frameworks from European Medicines Agency and Therapeutic Goods Administration. Reports often reference trial conduct in contexts involving specialists trained at Memorial Sloan Kettering Cancer Center, Cleveland Clinic, Vanderbilt University Medical Center, and trial oversight by boards such as Institutional Review Board panels including members affiliated with Yale School of Medicine.

Translational studies bridge laboratories at Broad Institute, Cold Spring Harbor Laboratory, and Sanger Institute with clinics at Mount Sinai Hospital, Beth Israel Deaconess Medical Center, and Stanford Cancer Institute. Articles discuss genomic sequencing collaborations that include The Cancer Genome Atlas, bioinformatics work from European Bioinformatics Institute, and precision oncology programs modeled after initiatives at Dana-Farber Cancer Institute and the NCI-MATCH trial. Contributions often build on discoveries associated with researchers from MIT, Princeton University, University of California, Berkeley, and collaborations with biotech firms like Illumina and Grail.

Content spans modalities—from immunotherapies developed in laboratories linked to University of Texas, cytotoxic regimens trialed at Roswell Park Comprehensive Cancer Center, to targeted inhibitors created by teams at Genentech and Bristol-Myers Squibb. Reports include outcomes from trials involving checkpoint inhibitors attributed to work by James P. Allison and Tasuku Honjo-related pathways, cell therapies evolved at City of Hope, and radiopharmaceuticals evaluated in centers like National Accelerator Facility. Multidisciplinary care models draw on experiences from Massachusetts General Hospital, UCL Hospitals, and Karolinska University Hospital.

The journal publishes biomarker validation studies developed with pathology departments at Mayo Clinic, imaging research from Johns Hopkins Hospital and Brigham and Women's Hospital, and circulating tumor DNA studies in collaboration with Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. Diagnostic advances often reference platforms created by Roche Diagnostics, companion diagnostics discussed with FDA guidance, and prognostic models influenced by epidemiologic work from International Agency for Research on Cancer and World Health Organization cancer programs.

Articles address regulatory approval pathways interacting with bodies such as Food and Drug Administration, European Medicines Agency, and Health Canada; ethical discussions reference committees at institutions like Harvard School of Public Health and legal frameworks exemplified by rulings in courts like the Supreme Court of the United States when relevant. Patient-centered research involves advocacy organizations including American Cancer Society, survivorship programs modeled by St. Jude Children's Research Hospital, and patient-reported outcome instruments developed in collaboration with groups at University College London and Johns Hopkins University.

The journal highlights challenges faced by research networks such as Cooperative Human Tissue Network and anticipates advances from technologies developed at CRISPR Therapeutics, Editas Medicine, and sequencing platforms by Pacific Biosciences. Future directions include artificial intelligence tools created in partnerships with researchers at Google DeepMind, digital pathology initiatives from Philips Healthcare, and global trial expansion involving centers in Singapore General Hospital, All India Institute of Medical Sciences, and Aga Khan University Hospital.

Category:Oncology journals Category:Medical journals